Egetis Therapeutics: Positive CHMP opinion for Emcitate - Redeye

Redeye comments on the positive news that Emcitate has received a positive CHMP opinion for MCT8 deficiency – and is close to commercialization of the drug. We raise our base case and look forward to next weeks investor day where we hope to learn more about the launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/1065092/egetis-therapeutics-positive-chmp-opinion-for-emcitate?utm_source=finwire&utm_medium=RSS